Benefits
LDL cholesterol and the LDL receptor pathway
In a crossover study, adults took a lunasin-enriched soy extract or placebo for 8 weeks. Total and LDL cholesterol edged down, but the changes were small and not statistically significant. In liver cells and in mice, lunasin lowered PCSK9 and raised LDL-receptor levels, which increased the clearance of LDL from the blood. The human readout did not confirm a cholesterol effect.
Absorption of the intact peptide after oral intake
Whether an intact peptide survives digestion is debated. After men ate 50 g of soy protein a day for 5 days, the intact lunasin peptide was measured in their blood, with an estimated 4.5% of the ingested amount reaching the circulation. Laboratory work suggests other soy protease inhibitors help shield lunasin from digestive enzymes so some of it stays intact.
Immune and inflammatory signaling in the gut
When samples of human intestinal tissue were exposed to lunasin outside the body, the peptide shifted immune signaling, raising regulatory messengers such as IL-10 and blunting an inflammatory response triggered by a bacterial molecule. This is laboratory work on donated tissue, not an outcome measured in people taking lunasin by mouth.
Innate immune cell activity
In immune cells grown in the laboratory and in mouse studies, lunasin activated dendritic cells and macrophages, raising surface markers and signaling molecules that help start an immune response, and it was tested as an add-on to experimental vaccines. In mice on a high-fat diet it shifted cytokine balance. These are cell and animal findings, not human results.
Mechanism of action
PCSK9 and the LDL receptor
In liver cells and in mice, lunasin lowers the protein PCSK9 and increases levels of the LDL receptor through the SREBP-2 pathway. More LDL receptors on liver cells pull more LDL cholesterol out of the blood. This pathway has been shown in cell and animal models, not confirmed as a cholesterol change in people.
Partial survival of digestion
Purified lunasin is broken down within minutes by simulated digestive fluids. When it is eaten as part of whole soy protein, the Bowman-Birk protease inhibitor and related soy compounds shield it, so a fraction of the peptide can reach the bloodstream intact, as seen in the human blood-absorption study.
NF-kB and cytokine signaling
In cell and animal models lunasin dampens NF-kB inflammatory signaling and lowers inflammatory messengers such as IL-6, TNF-alpha and MCP-1, while raising regulatory signals. These effects are consistent across several laboratory systems but have not been shown as clinical outcomes in people.
Activation of immune cells
In cultured dendritic cells and macrophages lunasin raises co-stimulatory surface markers and the output of cytokines and chemokines that prime an immune response. In mouse work it enhanced responses to experimental vaccines. The relevance of these cell and animal effects to everyday immune health in people is unknown.
Clinical trials
Triple-blind, placebo-controlled crossover trial of a lunasin-enriched soy extract at 335 mg a day for 8 weeks, with a 3-week washout between periods. (Haddad Tabrizi et al. 2020, J Diet Suppl)
31 adults (19 women, 12 men, mean age about 61).
Reductions in cardiometabolic markers were small and none reached statistical significance: total cholesterol fell by about 0.1 mmol/L and LDL cholesterol by about 0.07 mmol/L, with no significant change in triglycerides, glucose, insulin resistance, blood pressure, BMI or waist. The authors called for higher doses, larger samples and longer treatment to test any independent role of lunasin.
Study measuring the intact lunasin peptide in blood after soy protein intake, using antibody and mass-spectrometry detection. (Dia et al. 2009, J Agric Food Chem)
5 healthy men aged 18 to 25 who ate 50 g of soy protein a day for 5 days.
On day 5, the intact lunasin peptide was detected in plasma 30 minutes and 1 hour after intake at about 66 to 71 ng/mL, and was absent at baseline. The authors estimated that about 4.5% of the ingested lunasin was absorbed. This shows some intact peptide reaches the blood but does not measure any health outcome.
Ex vivo study conditioning donated human intestinal biopsies with lunasin, with and without a bacterial inflammatory trigger, then measuring gene and protein signaling. (Fernandez-Tome et al. 2021, Mol Nutr Food Res)
Intestinal biopsies from healthy human donors, cultured outside the body.
Lunasin remained stable in the cultured tissue and changed immune signaling, raising regulatory messengers IL-10 and TGF-beta and lowering NF-kB signaling. It also blunted a lipopolysaccharide-driven inflammatory response, reducing IL-17A, interferon-gamma and IL-8. These are tissue-level laboratory readouts, not outcomes in people taking lunasin by mouth.
Open-label, single-center, historically controlled 12-month trial of oral lunasin, with mostly virtual data collection (NCT02709330). (Bedlack et al. 2019, Amyotroph Lateral Scler Frontotemporal Degener)
50 people with amyotrophic lateral sclerosis.
There was no significant effect of lunasin on histone acetylation in blood or on disease progression. Side effects reported by participants were minor, and enrollment, retention and adherence were high. A null result; the trial is useful mainly for its human tolerability data and novel patient-centered design.
Laboratory study in human liver (HepG2) cells and in ApoE-deficient mice given lunasin by injection for 4 weeks. (Gu et al. 2017, Oncotarget)
Human liver cell cultures and ApoE-deficient mice (no human dosing).
Lunasin lowered PCSK9 and raised LDL-receptor levels, increasing LDL uptake in liver cells; the effect worked through HNF-1-alpha and the PI3K/Akt and SREBP-2 pathways. Injected mice had lower hepatic PCSK9, higher LDL receptor and lower blood total and LDL cholesterol. A mechanism study, not evidence of an oral cholesterol effect in people.
Laboratory study of a lunasin-enriched soybean extract and purified lunasin in macrophage and lymphocyte cell lines, with simulated digestion. (Paterson et al. 2023, Nutrients)
Mouse macrophage (RAW264.7) and lymphocyte (EL4) cell lines.
The extract scavenged free radicals, lowered reactive oxygen species and had immune-modulating effects, increasing nitric oxide, phagocytic activity and cytokine release in macrophages, with dose-dependent effects on lymphocytes. Some peptides resisted simulated digestion. All results are in cultured cells, not in people.
Study of lunasin given by injection to mice on a high-fat diet, measuring inflammatory and immune markers. (Hsieh et al. 2021, Food Chem Toxicol)
Male and female C57BL/6J mice on a high-fat diet.
Lunasin lowered inflammatory messengers (MCP-1, IL-1-beta, TNF-alpha) from peritoneal macrophages and reduced an oxidized-lipid marker in females, and normalized spleen changes and shifted cytokine output in males. Effects differed by sex. These are animal findings and do not establish an anti-inflammatory benefit in people.